ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
NBIX Description — Neurocrine Biosciences, Inc.

Neurocrine Biosciences is focused on discovering, developing, and commercializing pharmaceuticals, in diseases with unmet medical needs, through its research and development platform, focused on neurological and endocrine related diseases and disorders. Co.'s approved products are: INGREZZA® for the treatment of adults with tardive dyskinesia; and ORILISSA® (elagolix), an oral medication for the management of endometriosis associated with moderate to severe pain. Co.'s clinical development programs include, among others, elagolix for the treatment of Uterine Fibroids, opicapone for the treatment of Parkinson's disease, and NBI-74788 for the treatment of congenital adrenal hyperplasia.

Company Name:  Neurocrine Biosciences, Inc.
Website:  www.neurocrine.com
Sector:  Biotechnology
Number of ETFs Holding NBIX:  40
Total Market Value Held by ETFs:  $1,213,070,019
Total Market Capitalization:  $10,382,000,000
% of Market Cap. Held by ETFs:  11.68%
 ETF   NBIX Weight   NBIX Amount 
 VTI   0.03%   $290,572,114         
 VB   0.27%   $260,377,633         
 VBK   0.61%   $153,990,973         
 VXF   0.20%   $146,378,536         
 IBB   1.36%   $98,833,590         
 FBT   3.50%   $60,207,144         
 IWP   0.33%   $36,624,993         
 IWF   0.07%   $32,853,359         
 IWR   0.13%   $26,908,255         
 VHT   0.24%   $25,786,374         
List of all 40 ETFs holding NBIX »
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
Warren Buffett Dividend Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
Best Vanguard ETFs By TTM Performance
Worst Vanguard ETFs By TTM Performance
Best iShares ETFs By TTM Performance
Worst iShares ETFs By TTM Performance
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
Top 10 Analyst Rated Consumer Stocks
Top 10 Analyst Rated Dividend Stocks
Top 10 Analyst Rated Energy Stocks
Top 10 Analyst Rated Financial Stocks
Top 10 Analyst Rated Healthcare Stocks
Top 10 Analyst Rated REIT Stocks
Top 10 Analyst Rated Technology Stocks
Best Dividend Stocks 1999-2019
Best High Dividend Stocks 1999-2019
Top Dividend Stocks 2009-2019
Best High Yield Stocks 2009-2019
Top Dividend Stocks 2014-2019
Top High Dividend Yield Stocks 2014-2019
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Strong Buy (3.56 out of 4)
66th percentile
(ranked higher than approx. 66% of all stocks covered)

Analysts Forecast:
NBIX Price Target

Based on data provided by Zacks Investment Research via Quandl.com


PARTNER NEWS:

Mon, Nov 4, 6:15 PM, Zacks
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Mon, Oct 28, 7:30 AM, Zacks
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
CTLT vs. NBIX Which Stock Is the Better Value Option?

ETFs Holding NBIX | Neurocrine Biosciences, Inc. | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2019, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.